These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35964542)

  • 21. Tau-PET imaging predicts cognitive decline and brain atrophy progression in early Alzheimer's disease.
    Lagarde J; Olivieri P; Tonietto M; Tissot C; Rivals I; Gervais P; Caillé F; Moussion M; Bottlaender M; Sarazin M
    J Neurol Neurosurg Psychiatry; 2022 May; 93(5):459-467. PubMed ID: 35228270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of deposition of tau and amyloid-β proteins with structural connectivity changes in cognitively normal older adults and Alzheimer's disease spectrum patients.
    Shigemoto Y; Sone D; Maikusa N; Okamura N; Furumoto S; Kudo Y; Ogawa M; Takano H; Yokoi Y; Sakata M; Tsukamoto T; Kato K; Sato N; Matsuda H
    Brain Behav; 2018 Dec; 8(12):e01145. PubMed ID: 30358161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals.
    Biel D; Brendel M; Rubinski A; Buerger K; Janowitz D; Dichgans M; Franzmeier N;
    Alzheimers Res Ther; 2021 Aug; 13(1):137. PubMed ID: 34384484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.
    Hartley SL; Fleming V; Schworer EK; Peven J; Handen BL; Krinsky-McHale S; Hom C; Lee L; Tudorascu DL; Laymon C; Minhas D; Luo W; Cohen A; Zaman S; Ances BM; Mapstone M; Head E; Lai F; Rosas HD; Klunk W; Christian B;
    J Alzheimers Dis; 2023; 95(1):213-225. PubMed ID: 37482997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
    Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
    Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA
    Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes.
    Jack CR; Wiste HJ; Botha H; Weigand SD; Therneau TM; Knopman DS; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Lowe VJ; Vemuri P; Mielke MM; Fields JA; Machulda MM; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
    Brain; 2019 Oct; 142(10):3230-3242. PubMed ID: 31501889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy.
    Whitwell JL; Ahlskog JE; Tosakulwong N; Senjem ML; Spychalla AJ; Petersen RC; Jack CR; Lowe VJ; Josephs KA
    Parkinsonism Relat Disord; 2018 Mar; 48():3-9. PubMed ID: 29254665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A
    Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Impact of Amyloid-β or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease.
    Jang H; Kim HJ; Choe YS; Kim SJ; Park S; Kim Y; Kim KW; Lyoo CH; Cho H; Ryu YH; Choi JY; DeCarli C; Na DL; Seo SW;
    J Alzheimers Dis; 2020; 78(2):573-585. PubMed ID: 33016911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue.
    Lemoine L; Ledreux A; Mufson EJ; Perez SE; Simic G; Doran E; Lott I; Carroll S; Bharani K; Thomas S; Gilmore A; Hamlett ED; Nordberg A; Granholm AC
    Mol Neurodegener; 2020 Nov; 15(1):68. PubMed ID: 33222700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
    Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
    Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
    Dani M; Wood M; Mizoguchi R; Fan Z; Walker Z; Morgan R; Hinz R; Biju M; Kuruvilla T; Brooks DJ; Edison P
    Brain; 2018 Sep; 141(9):2740-2754. PubMed ID: 30052812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment.
    King-Robson J; Wilson H; Politis M;
    J Alzheimers Dis; 2021; 82(2):541-560. PubMed ID: 34057079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
    Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
    Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.
    Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ
    J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Emerging β-Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults.
    Farrell ME; Papp KV; Buckley RF; Jacobs HIL; Schultz AP; Properzi MJ; Vannini P; Hanseeuw BJ; Rentz DM; Johnson KA; Sperling RA
    Neurology; 2022 Apr; 98(15):e1512-e1524. PubMed ID: 35338074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyloid-dependent and amyloid-independent effects of Tau in individuals without dementia.
    Therriault J; Pascoal TA; Sefranek M; Mathotaarachchi S; Benedet AL; Chamoun M; Lussier FZ; Tissot C; Bellaver B; Lukasewicz PS; Zimmer ER; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P;
    Ann Clin Transl Neurol; 2021 Oct; 8(10):2083-2092. PubMed ID: 34617688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repetitive negative thinking is associated with amyloid, tau, and cognitive decline.
    Marchant NL; Lovland LR; Jones R; Pichet Binette A; Gonneaud J; Arenaza-Urquijo EM; Chételat G; Villeneuve S;
    Alzheimers Dement; 2020 Jul; 16(7):1054-1064. PubMed ID: 32508019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.
    Groot C; Smith R; Stomrud E; Binette AP; Leuzy A; Wuestefeld A; Wisse LEM; Palmqvist S; Mattsson-Carlgren N; Janelidze S; Strandberg O; Ossenkoppele R; Hansson O
    Brain; 2023 Apr; 146(4):1580-1591. PubMed ID: 36084009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.